Our News

Published Scientific Articles

Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells

Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4

Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma

Inflammatory Mediators of Esophagitis Alter p27Kip1 Expression in Esophageal Epithelial Cells

Concarlo in the News

Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway

Many startups are built off research, so why don’t more scientists become founders?

CDK Inhibitors: Why Women – and Men – Should Know About This ‘New Era’ Of Cancer Treatment

Webinars & Talks

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

LabOps: Changing Outcomes for Drug-Resistant Patients with Stacy Blain, Founder, and CSO at Concarlo Therapeutics

Case Study: Developing liposomal formulation of a novel 91-mer synthetic peptide for treatment of ER+ CDK4i resistant Breast Cancer


“The reward for work well done is the opportunity to do more”

—Jonas Salk

RESI’s Innovator’s Pitch Challenge Winner

Princeton University Women’s Showcase

The 50 Most admired companies: CIO Bio

Top 100 entreprenuers: Alumni List

Top Biotech Startup 2022
Awarded by: Life Sciences Review